4D Molecular Therapeutics, Inc.
FDMTDrugs in Pipeline
7
Phase 3 Programs
2
Upcoming Catalysts
3
Next Catalyst
Jun 15, 2026
13wMarket Overview
Stock performance and key metrics
3 upcoming, 0 past
4D-150 IVT (3E10 vg/eye)
Neovascular Age-Related Macular Degeneration (nAMD)
EYLEA® (aflibercept) Injection 2 mg (0.05mL)
Macular Neovascularization Secondary to Age-Related Macular Degeneration
4D-150 IVT
Diabetic Macular Edema
Aflibercept IVT
Neovascular (Wet) Age-Related Macular Degeneration
4D-125 IVT Injection
X-Linked Retinitis Pigmentosa
4D-310
Fabry Disease
4D-710
Cystic Fibrosis Lung
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
4D-150 IVT (3E10 vg/eye) | Phase 3 | Neovascular Age-Related Macular Degeneration (nAMD) | - | - |
EYLEA® (aflibercept) Injection 2 mg (0.05mL) | Phase 3 | Macular Neovascularization Secondary to Age-Related Macular Degeneration | - | - |
4D-150 IVT | Phase 2 | Diabetic Macular Edema | - | - |
Aflibercept IVT | Phase 2 | Neovascular (Wet) Age-Related Macular Degeneration | - | - |
4D-125 IVT Injection | Phase 2 | X-Linked Retinitis Pigmentosa | - | - |
4D-310 | Phase 2 | Fabry Disease | - | - |
4D-710 | Phase 2 | Cystic Fibrosis Lung | - | - |